Thumbnail Image

The immunological landscape in pancreatic ductal adenocarcinoma and overcoming resistance to immunotherapy

Location : 8
Library location : Review

Attachments [0]

More Detail

Issue Date : 2023-10-19T22:30:01Z
Abstract :
Pancreatic ductal adenocarcinoma is associated with a poor prognosis and there are few treatment options. The development of immunotherapy in pancreatic ductal adenocarcinoma has been difficult, and immune checkpoint inhibitors are only effective in a very small subset of patients. Most obstacles for treatment have been related to intertumoural and intratumoural heterogeneity, the composition of tumour stroma, and crosstalk with cancer cells. Improved molecular characterisation of pancreatic ductal adenocarcinoma and a better understanding of its microenvironment have paved the way for novel immunotherapy strategies, including the identification of predictive biomarkers, the development of rational combinations to optimise effectiveness, and the targeting of new mechanisms.
Comments (Leave your Comments here about this item.)

Related items (Items from the same collection.)

Now showing 1 - 20 of 295